Yahoo Finance

Estimated Discount To Fair Value: 12.1%

Genomma Lab Internacional is trading at MX$24.87, slightly below its estimated fair value of MX$28.3, suggesting some undervaluation based on cash flows. Recent earnings showed a significant turnaround with net income for Q4 2024 reaching MX$473.49 million from a loss the previous year, and annual sales growing to MX$18.61 billion. Though revenue growth is moderate at 7.9% annually, it surpasses the market average of 6.8%.

• According our earnings growth report, there's an indication that Genomma Lab Internacional. de might be ready to expand.

• Dive into the specifics of Genomma Lab Internacional. de here with our thorough financial health report.

Kadokawa

Overview: Kadokawa Corporation is a Japanese entertainment company with a market cap of ¥510.18 billion, engaging in various media and content production activities.

Operations: Kadokawa Corporation's revenue is primarily derived from Publishing and IP Creation at ¥149.50 billion, followed by Animation and Live-Action Footage at ¥50.10 billion, Game at ¥32.55 billion, Web Service at ¥18.43 billion, and Education/Edtech at ¥14.91 billion.

Estimated Discount To Fair Value: 27.1%

Kadokawa is trading at ¥3,632, significantly below its estimated fair value of ¥4,985.51, presenting an undervaluation based on cash flows. The company's earnings grew by 82% last year and are forecast to increase by 25.5% annually over the next three years, outpacing the JP market's growth rate of 8%. Despite a highly volatile share price recently and a low future return on equity forecast of 9.8%, revenue is expected to grow faster than the market average.

• Upon reviewing our latest growth report, Kadokawa's projected financial performance appears quite optimistic.

• Navigate through the intricacies of Kadokawa with our comprehensive financial health report here.

Summing It All Up

• Get an in-depth perspective on all 504 Undervalued Global Stocks Based On Cash Flows by using our screener here.

• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.

• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BMV:GMXT * BMV:LAB B and TSE:9468.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com